{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T06:51:21Z","timestamp":1776840681578,"version":"3.51.2"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070168"],"award-info":[{"award-number":["82070168"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20418"],"award-info":[{"award-number":["U23A20418"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470227"],"award-info":[{"award-number":["82470227"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81830004"],"award-info":[{"award-number":["81830004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2020CXJQ02"],"award-info":[{"award-number":["2020CXJQ02"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014137","name":"Shanghai Shenkang Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2024CRI039"],"award-info":[{"award-number":["SHDC2024CRI039"]}],"id":[{"id":"10.13039\/501100014137","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA1100800"],"award-info":[{"award-number":["2021YFA1100800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.retram.2024.103477","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T02:55:22Z","timestamp":1729652122000},"page":"103477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["CAR T-cell therapy combined with autologous hematopoietic cell transplantation in patients with refractory\/relapsed Burkitt Lymphoma"],"prefix":"10.1016","volume":"73","author":[{"given":"Yifan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gangfeng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanfang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yadi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cailu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiguang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aibin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.retram.2024.103477_bib0001","first-page":"19","article-title":"Etiology of Burkitt's lymphoma\u2013an alternative hypothesis to a vectored virus","volume":"42","author":"Burkitt","year":"1969","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"10.1016\/j.retram.2024.103477_bib0002","first-page":"1124","article-title":"Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy","volume":"135","author":"Woessmann","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.retram.2024.103477_bib0003","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/pbc.21585","article-title":"The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan","volume":"51","author":"Fujita","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"10.1016\/j.retram.2024.103477_bib0004","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3109\/10428194.2012.677534","article-title":"Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia","volume":"53","author":"Anoop","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.retram.2024.103477_bib0005","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3324\/haematol.2014.121434","article-title":"Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective \"Lymphomes Malins B\" protocols. A Soci\u00e9t\u00e9 Fran\u00e7aise des Cancers de l'Enfant study","volume":"100","author":"Jourdain","year":"2015","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.retram.2024.103477_bib0006","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/bjh.15491","article-title":"Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB\/LMB 96: a report from the FAB\/LMB 96 study group","volume":"182","author":"Cairo","year":"2018","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.retram.2024.103477_bib0007","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bbmt.2012.11.016","article-title":"Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research","volume":"19","author":"Maramattom","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2024.103477_bib0008","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2021-145544","article-title":"Efficacy of autologous stem cell transplantation in adult burkitt\/burkitt-like lymphoma: a systematic review","volume":"138","author":"Joshi","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.retram.2024.103477_bib0009","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tmrv.2019.08.003","article-title":"Anti-CD19 CAR T-cell therapy for B-cell non-hodgkin lymphoma","volume":"34","author":"Abramson","year":"2020","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.retram.2024.103477_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102443","article-title":"Treatment strategies for patients with diffuse large B-cell lymphoma","volume":"110","author":"Poletto","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"10.1016\/j.retram.2024.103477_bib0011","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1080\/10428194.2022.2076853","article-title":"Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience","volume":"63","author":"Seitter","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.retram.2024.103477_bib0012","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1007\/s00262-021-02850-6","article-title":"CAR19\/22 T cell therapy in adult refractory Burkitt's lymphoma","volume":"70","author":"Zhou","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"20","key":"10.1016\/j.retram.2024.103477_bib0013","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.retram.2024.103477_bib0014","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.retram.2024.103477_bib0015","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jamaoncol.2020.4643","article-title":"Site-specific and targeted therapy based on molecular profiling by next-generation sequencing for cancer of unknown primary site: a nonrandomized phase 2 clinical trial","volume":"6","author":"Hayashi","year":"2020","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.retram.2024.103477_bib0016","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00000421-199406000-00002","article-title":"The role of prognostic factors in treatment selection for early-stage Hodgkin's disease","volume":"17","author":"Mendenhall","year":"1994","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"10.1016\/j.retram.2024.103477_bib0017","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2214\/ajr.138.2.229","article-title":"Importance of initial mediastinal adenopathy in Hodgkin disease","volume":"138","author":"North","year":"1982","journal-title":"AJR Am J Roentgenol"},{"issue":"12","key":"10.1016\/j.retram.2024.103477_bib0018","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/annonc\/mdt413","article-title":"Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions","volume":"24","author":"Klimm","year":"2013","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.retram.2024.103477_bib0019","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1080\/10428190701559140","article-title":"Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans","volume":"48","author":"Picardi","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.retram.2024.103477_bib0020","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.retram.2024.103477_bib0021","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.retram.2024.103477_bib0022","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.retram.2024.103477_bib0023","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.3324\/haematol.2021.280257","article-title":"Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study","volume":"107","author":"Dourthe","year":"2022","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.retram.2024.103477_bib0024","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.retram.2024.103477_bib0025","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-all","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.retram.2024.103477_bib0026","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41409-018-0235-0","article-title":"CAR T cells induce a complete response in refractory Burkitt Lymphoma","volume":"53","author":"Avigdor","year":"2018","journal-title":"Bone Marrow Transplantation"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2024.103477_bib0027","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2023-184692","article-title":"CAR T- cell therapy provides an opportunity for further consolidation treatment for relapsed or refractory adult burkitt lymphoma patients","volume":"142","author":"Liu","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.retram.2024.103477_bib0028","doi-asserted-by":"crossref","first-page":"7571","DOI":"10.1200\/JCO.2023.41.16_suppl.7571","article-title":"Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma","volume":"41","author":"Samples","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.retram.2024.103477_bib0029","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.retram.2024.103477_bib0030","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.retram.2024.103477_bib0031","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.retram.2024.103477_bib0032","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2020006770","article-title":"Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies","volume":"137","author":"Gauthier","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.retram.2024.103477_bib0033","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.retram.2024.103477_bib0034","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.retram.2024.103477_bib0035","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients","volume":"31","author":"Pan","year":"2017","journal-title":"Leukemia"},{"issue":"10299","key":"10.1016\/j.retram.2024.103477_bib0036","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.retram.2024.103477_bib0037","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(23)00436-9","article-title":"Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study","volume":"24","author":"Pan","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.retram.2024.103477_bib0038","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.retram.2024.103477_bib0039","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41375-021-01345-8","article-title":"Long-term activity of tandem CD19\/CD20 CAR therapy in refractory\/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.retram.2024.103477_bib0040","first-page":"1632","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"issue":"7750","key":"10.1016\/j.retram.2024.103477_bib0041","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.retram.2024.103477_bib0042","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.2147\/OTT.S235882","article-title":"Sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells for a pediatric Ph-like B-ALL patient that relapsed after CART-cell and haplo-HSCT therapy: a case report and review of literature","volume":"13","author":"Hua","year":"2020","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10.1016\/j.retram.2024.103477_bib0043","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.retram.2024.103477_bib0044","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41408-023-00819-5","article-title":"Which one is better for refractory\/relapsed acute B-cell lymphoblastic leukemia: single-target (CD19) or dual-target (tandem or sequential CD19\/CD22) CAR T-cell therapy?","volume":"13","author":"Liu","year":"2023","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.retram.2024.103477_bib0045","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.retram.2024.103477_bib0046","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1182\/blood.2019002008","article-title":"Early response observed in pediatric patients with relapsed\/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells","volume":"135","author":"Zhang","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.retram.2024.103477_bib0047","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/bloodadvances.2021004557","article-title":"Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory\/relapsed Burkitt lymphoma","volume":"6","author":"Liu","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.retram.2024.103477_bib0048","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-022-00924-0","article-title":"Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT","volume":"7","author":"Wei","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.retram.2024.103477_bib0049","article-title":"Case report: sandwich therapy of CAR-T combined with ASCT: sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed\/refractory Burkitt's lymphoma with TP53 mutations","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.retram.2024.103477_bib0050","article-title":"CD19\/CD22 chimeric antigen receptor T cell cocktail therapy following autologous transplantation in patients with relapsed\/refractory aggressive B cell lymphomas","volume":"27","author":"Cao","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.retram.2024.103477_bib0051","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1002\/ctm2.176","article-title":"Long-term outcomes of relapsed\/refractory double-hit lymphoma (r\/r DHL) treated with CD19\/22 CAR T-cell cocktail therapy","volume":"10","author":"Wei","year":"2020","journal-title":"Clin Transl Med"},{"issue":"11","key":"10.1016\/j.retram.2024.103477_bib0052","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","article-title":"NCCN Guidelines\u00ae insights: b-cell lymphomas, version 6.2023","volume":"21","author":"Zelenetz","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"30","key":"10.1016\/j.retram.2024.103477_bib0053","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.retram.2024.103477_bib0054","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jtct.2022.11.013","article-title":"Donor CD7 chimeric antigen receptor T cell bridging to allogeneic hematopoietic stem cell transplantation for T cell hematologic malignancy","volume":"29","author":"Li","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.retram.2024.103477_bib0055","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.retram.2024.103477_bib0056","doi-asserted-by":"crossref","first-page":"e30166","DOI":"10.1002\/pbc.30166","article-title":"Allogeneic CD34(+) selected hematopoietic stem cell boost following CAR T-cell therapy in a patient with prolonged cytopenia and active infection","volume":"70","author":"Lipsitt","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"16","key":"10.1016\/j.retram.2024.103477_bib0057","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1182\/bloodadvances.2022007572","article-title":"CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy","volume":"6","author":"Mullanfiroze","year":"2022","journal-title":"Blood Advances"},{"issue":"4","key":"10.1016\/j.retram.2024.103477_bib0058","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008857","article-title":"Combinational therapy of CAR T-cell and HDT\/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed\/refractory large B-cell lymphoma","volume":"12","author":"Liu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.retram.2024.103477_bib0059","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-06830-3","article-title":"Identification of genomic signatures in bone marrow associated with clinical response of CD19 CAR T-cell therapy","volume":"12","author":"Shao","year":"2022","journal-title":"Scientific Reports"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318624000394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318624000394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T18:34:15Z","timestamp":1762626855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318624000394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2452318624000394"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2024.103477","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T-cell therapy combined with autologous hematopoietic cell transplantation in patients with refractory\/relapsed Burkitt Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2024.103477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103477"}}